All News

While 20% of US adults choose not to wash their hands at appropriate times, nearly half admitted to forgetting to do it, according to a new national survey.

DDW 2025. Colonoscopic delivery of fecal therapy prevented recurrent C. diff infection in 95% of participants for 8 weeks, with mild GI adverse events reported by <10%.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

DDW 2025. Follow-up colonoscopy after a positive stool-based test was superior among adults aged 45-49 and across diverse populations whose original test was mt-sDNA.

Your daily dose of the clinical news you may have missed.

Measles, declared eradicated in the US 25years ago, has infected 900 Americans and is responsible for 3 deaths of children younger than age 5. How did we get here?

A simple RNA-based blood test can identify the risk of hypertensive disorders in pregnancy months before symptoms appear, researchers reported.

ACP 2025: Dr Fakorede outlines PAD risk amplifiers, polyvascular disease connections, and when to screen using ABI, TBI, or exercise testing in high-risk patients.

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

Affordability is pushing an increase in deferred care — even among the insured —and physicians are feeling the effects.

Your daily dose of the clinical news you may have missed.

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

ACP 2025: Foluso Fakorede, MD, discusses the importance of recognizing and screening for peripheral artery disease in primary care.

New clinical trial findings to be presented at ATS 2025 highlights the effectiveness of dupilumab in treating COPD and asthma.

The only approved DHE nasal powder addresses persistent limitations of existing DHE formulations, including liquid nasal sprays and injectables, Satsuma stated.

Nearly 1 in 10 US adults have eczema, with 18% experiencing multiple eczema conditions, researchers from the National Eczema Association reported.

Mepolizumab also cut annualized exacerbation rates by 21% across the full study cohort and by 31% in a subgroup of participants with chronic bronchitis only.